Big Pharma's Latest Move: Acquisition Unlocks $15 Million Market Opportunity in the U.S.!
Pharma Company Expands Injectable Portfolio with New Launch Targeting U.S. Hospital Market
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. The product is expected to deliver the same therapeutic benefits as Acetadote® Injection by Cumberland Pharmaceuticals Inc. Glenmark acquired the Abbreviated New Drug Application (ANDA) for this product from Aspen Pharma USA Inc.
Market Opportunity
The Acetadote® Injection market in the U.S. reported annual sales of approximately $15.2 million for the 12-month period ending January 2025, according to IQVIA sales data. Glenmark aims to capitalize on this market opportunity and strengthen its injectable portfolio in the U.S. hospital segment.
Leadership Comments
Marc Kikuchi, President & Business Head of Glenmark North America, highlighted the strategic importance of this launch, stating that it aligns with the company's growth strategy in the U.S. hospital market. He emphasized the addition of Acetylcysteine Injection as a valuable product for healthcare providers.
Company Overview
Glenmark Pharmaceuticals Ltd. is a global, research-driven pharmaceutical company operating across Branded, Generics, and OTC segments. The company focuses on therapeutic areas such as respiratory, dermatology, and oncology. Glenmark has 11 manufacturing facilities across four continents and operates in over 80 countries.
Financial Performance
For the latest financial period, Glenmark reported a consolidated revenue of Rs. 33,876 million, marking a 35.1% year-on-year growth. The India business contributed Rs. 10,637 million, while the European segment showed a 14.8% growth. The company achieved an EBITDA of Rs. 6,002 million with a margin of 17.7%, and a PAT of Rs. 3,480 million with a margin of 10.3%.
Future Prospects
With a strong focus on research and development, Glenmark aims to continue expanding its product offerings and enhance its presence in key markets. The company is also committed to sustainable growth, with its Green House Gas (GHG) emission reduction targets approved by the Science Based Target initiative (SBTi).
Disclaimer: This article is for informational purposes only and not investment advice.